argenx to Report Full Year 2021 Financial Results and Fourth Quarter Business Update on March 3, 2022
Breda, the Netherlands
argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, March 3, 2022 at 2:30 pm CET (8:30 am ET) to discuss its full year 2021 financial results and provide a fourth quarter business update.
A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the call.
Please dial in 15 minutes prior to the live call.
|Belgium||32 800 50 201|
|France||33 800 943355|
|Netherlands||31 20 795 1090|
|United Kingdom||44 800 358 0970|
|United States||1 888 415 4250|
|Japan||81 3 4578 9752|
|Switzerland||41 43 210 11 32|
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S. and Japan. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.
For further information, please contact:
Joke Comijn (EU)